ACTRN12624000191594尚未招募Unknown
Investigating tolvaptan stimulated copeptin measurements for the differential diagnosis of polyuria-polydipsia syndrome
Princess Alexandra Hospital, Metro South Health Service0 个研究点目标入组 40 人开始时间: 2024年2月27日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Diagnosis
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Healthy participants
- •oAge >18 years
- •oHealthy participant with no significant comorbidities
- •Participants with arginine vasopressin deficiency or primary polydipsia
- •- 18 years or older
- •- BMI 18.5 to 30 kg/m2
- •- polyuria >3L/day or >50mL/kg body weight/day or regular desmopressin administration.
排除标准
- •Healthy volunteers
- •oBMI <18.5 kg/m2 or >30 kg/m2
- •oVigorous physical exercise within 24 hours of study participation
- •oAlcohol intake or cigarette smoking within 24 hours of study participation
- •oPregnancy and breastfeeding
- •oEvidence of disordered drinking habits (polyuria >50 mL/kg body weight and polydipsia >3L/24 hours)
- •oAcute illness
- •oElectrolyte abnormalities including hyponatraemia or other electrolyte disorders
- •oSignificant medical comorbidities (cardiac, hepatic and kidney failure, diabetes mellitus, pituitary or adrenal disorders, untreated hypothyroidism, uncontrolled hypertension and epilepsy)
- •oConcomitant medications with the potential to interfere with the results (including those known to cause electrolyte disturbances and/or solute diuresis such as diuretics, glucocorticoids, anti-epileptic, anti-depressant and anti-emetic medications).
- •Participants with arginine vasopressin deficiency or primary polydipsia
- •o Vigorous exercise <24 hours before study participation
- •oAlcohol intake or cigarette smoking <24 hours before the study participation, pregnancy or breastfeeding
- •oAacute illness.
- •oSignificant medical comorbidities (cardiac, hepatic and kidney failure, diabetes mellitus, pituitary or adrenal disorders, untreated hypothyroidism, uncontrolled hypertension and epilepsy)
- •oConcomitant medications with the potential to interfere with the results (including those known to cause electrolyte disturbances and/or solute diuresis such as diuretics, glucocorticoids, anti-epileptic, anti-depressant and anti-emetic medications).
研究者
相似试验
尚未招募
不适用
The effects of tolvaptan treatment and copeptin concentration on renal prognosis in patients with chronic kidney disease or nephrotic syndrome, who have heart failure symptoms.Patients exhibit heart failure symptoms with chronic kidney disease (eGFR less than 60 mL/min/1.73 m2 for 3 months or more) or nephrotic syndrome (urinary protein excretion greater than 3.5 g/24hours, and hypoalbuminemia : less than 3.0 g/dL) .JPRN-UMIN000014980Department of Medicine, Kidney Center, Tokyo Women's Medical University50
尚未招募
不适用
A study of Tolvaptan to investigate the pharmacokinetics and diuretic effectcongestive heart failureJPRN-UMIN000006726Kanagawa Children's Medical Center10
招募中
4 期
The efficacy of tolvaptan in a population with congestive heart failure and chronic kidney disease: A multicenter, randomized, open label, blind endpoint study (AQUAKID-Study)congestive heart failure and chronic kidney diseaseJPRN-UMIN000012006Fujita Health University School of Medicine100
招募中
不适用
A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.ephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneJPRN-UMIN000021708Department of Nephrology and Endocrinology, The University of Tokyo Hospital3
招募中
不适用
Examination of efficacy of tolvaptan for chronic congective heart failure complicated with chronic kidney disease.Chronic congestive heart failureJPRN-UMIN000014312Department of Cardiology, Gifu University Graduate School of Medicine20